Two drugs better than one in relapsed indolent lymphoma

The addition of lenalidomide to rituximab extends progression-free survival by two years, US study shows

Patients with relapsed or refractory indolent non-Hodgkin lymphoma enjoy two years of progression-free survival when lenalidomide is added to routine rituximab teatment, a study shows.

Intravenous drug

US researchers randomised 358 patients to IV rituximab plus either oral lenalidomide or placebo for 12 treatment cycles in the phase 3 clinical trial funded by the manufacturer of lenalidomide.

All patients (median age 63) had relapsed or refractory follicular or marginal-zone lymphoma and 24%